DiaMedica Therapeutics Inc. (DMAC) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 83% of 52W Range • RSI-14 at 63 (BULLISH MOMENTUM)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While DMAC currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.61) and Max Pain ($10.00) forces dealer call-delta covering toward $10.94.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
DiaMedica Therapeutics Inc. (DMAC) dropped -3.05% to $9.52, trading at 83% of its 52-week range ($5.25 – $10.42). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
MINNEAPOLIS, October 22, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic s
Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-EstimationInterim Analysis Results Expected in Q1 2027
MINNEAPOLIS, October 19, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction (FGR) and acute isch
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on DMAC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for DMAC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, DiaMedica Therapeutics Inc. (DMAC) ranks #839 by composite RQD confidence (34/100, grade E) and #445 by equity capitalization ($513.4M). Within this direct 5-issuer industry benchmark cohort, DMAC leads on earnings valuation at N/A trailing P/E, while ARVN leads on capital efficiency and profitability with -32.1% ROIC and — gross margin. OCS currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with DMAC at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DMAC
ACTIVE
DiaMedica Therapeutics Inc. | E | 34/100 | — | — | -35.0% | -3.05% | $513.4M | Benchmark Subject |
| INDP Indaptus Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | +0.30% | $513.0M | /indp-vs-dmac → |
| ARVN Arvinas Inc. | D- | 37/100 | — | — | -32.1% | +3.95% | $516.6M | /arvn-vs-dmac → |
| OCS Oculis Holding AG | D+ | 58/100 | — | — | — | +3.26% | $507.5M | /ocs-vs-dmac → |
| AQST Aquestive Therapeutics Inc. | E | 27/100 | — | 58.3% | -35.0% | -4.49% | $507.1M | /aqst-vs-dmac → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), DiaMedica Therapeutics Inc. (DMAC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$32.8M, operating cash flow of -$29.1M, and free cash flow of -$29.1M (-31.7% YoY). On the balance sheet, DMAC closed FY2025 with $61.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$32.8M | -$29.1M | -$29.1M | $61.4M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$24.4M | -$22.1M | -$22.1M | $46.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$19.4M | -$18.7M | -$18.7M | — | — |
As of 2026-11-01, DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $9.52 (-3.05% 1D, market cap $513.4M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DMAC ranks #839 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), DMAC carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INDP (Indaptus Therapeutics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $513.0M) and ARVN (Arvinas Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -32.1%, cap $516.6M). Among the 5-stock peer group, DMAC leads on earnings multiple (N/A) while ARVN leads on capital efficiency (-32.1% ROIC).
Per DMAC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001401040), DiaMedica Therapeutics Inc. generated $0 in revenue, -$32.8M in net income, and -$29.1M in free cash flow against $61.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
DMAC last traded at $9.52 (-3.05% on volume of 196,521 shares), positioning the stock +25.10% above its 50-day simple moving average ($7.61) and +33.90% above its 200-day simple moving average ($7.11). Across its 52-week range of $5.25 to $10.42, DMAC sits at the 82.6% percentile with a 14-day RSI of 63.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.33 to $10.71).
Why DMAC Stock dropped -3.05% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.